Introduction The pharmaceutical world is buzzing with excitement over Retatrutide, Eli Lilly’s innovative triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors. As the successor to blockbuster drugs like Mounjaro (Tirzepatide) and Wegovy (Semaglutide), Retatrutide promises even greater weight…

? Retatrutide Overview Retatrutide (Eli Lilly’s triple-hormone agonist) is the next-generation obesity and type 2 diabetes treatment, outperforming Wegovy® and Mounjaro® in clinical trials with 24.2% average weight loss at 48 weeks. As…

I. Pharmacological Differences A. Molecular Mechanisms B. Receptor Binding Affinities Receptor Tirzepatide EC50 Semaglutide EC50 GLP-1 0.11 nM 0.04 nM GIP 0.08 nM N/A II. Head-to-Head Clinical Comparisons A. SURPASS-6…

1. Clinical Trial Data (SURMOUNT Series) 2. Real User Case Studies 3. Comparative Analysis 4. Usage Guidelines Compliance Note:“Tirzepatide is FDA-approved as Zepbound™ for chronic weight management in adults with…